Absci
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creat...
Latest News
4 days ago · seekingalpha.com
Absci Corporation (ABSI) Q3 2026 Earnings Call TranscriptAbsci Corporation (ABSI) Q3 2026 Earnings Call Transcript
4 days ago · marketbeat.com
Absci Q3 Earnings Call HighlightsAbsci NASDAQ: ABSI expects to release interim data from its experimental pattern hair loss treatment in December, followed by a fuller assessment in early 2027, executives said during the company's third-quarter business update on November 12.
4 days ago · zacks.com
Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue EstimatesAbsci Corporation (ABSI) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.2 per share a year ago.
4 days ago · globenewswire.com
Absci Reports Business Updates and Third Quarter 2026 Financial and Operating ResultsABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month
4 days ago · globenewswire.com
Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader PipelineGlobal commercial executive brings a track record of launching prescription biologics and building consumer-driven brands at Galderma, Allergan and GSK Global commercial executive brings a track record of launching prescription biologics and building consumer-driven brands at Galderma, Allergan and GSK
5 days ago · seekingalpha.com
Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference TranscriptAbsci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
21 days ago · globenewswire.com
Absci to Participate in Upcoming Investor ConferencesVANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference (Boston, MA) Fireside chat on Tuesday, November 10th at 1:00 p.m.
1 month ago · globenewswire.com
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2026 before market open on Thursday, November 12, 2026.
2 months ago · globenewswire.com
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for EndometriosisPhase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept.
2 months ago · seekingalpha.com
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptAbsci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ABSI